PELIOSIS HEPATIS, A CONDITION IN WHICH LIVER AND SOMETIMES SPLENIC TISSUE IS REPLACED WITH BLOOD-FILLED CYSTS, HAS BEEN REPORTED IN PATIENTS RECEIVING ANDROGENIC ANABOLIC STEROID THERAPY. THESE CYSTS ARE SOMETIMES PRESENT WITH MINIMAL HEPATIC DYSFUNCTION, BUT AT OTHER TIMES THEY HAVE BEEN ASSOCIATED WITH LIVER FAILURE. THEY ARE OFTEN NOT RECOGNIZED UNTIL LIFE-THREATENING LIVER FAILURE OR INTRA-ABDOMINAL HEMORRHAGE DEVELOPS. WITHDRAWAL OF DRUG USUALLY RESULTS IN COMPLETE DISAPPEARANCE OF LESIONS. LIVER CELL TUMORS ARE ALSO REPORTED. MOST OFTEN THESE TUMORS ARE BENIGN AND ANDROGEN-DEPENDENT, BUT FATAL MALIGNANT TUMORS HAVE BEEN REPORTED. WITHDRAWAL OF DRUG OFTEN RESULTS IN REGRESSION OR CESSATION OF PROGRESSION OF THE TUMOR. HOWEVER, HEPATIC TUMORS ASSOCIATED WITH ANDROGENS OR ANABOLIC STEROIDS ARE MUCH MORE VASCULAR THAN OTHER HEPATIC TUMORS AND MAY BE SILENT UNTIL LIFE-THREATENING INTRA-ABDOMINAL HEMORRHAGE DEVELOPS. BLOOD LIPID CHANGES THAT ARE KNOWN TO BE ASSOCIATED WITH INCREASED RISK OF ATHEROSCLEROSIS ARE SEEN IN PATIENTS TREATED WITH ANDROGENS OR ANABOLIC STEROIDS. THESE CHANGES INCLUDE DECREASED HIGH-DENSITY LIPOPROTEINS AND SOMETIMES INCREASED LOW-DENSITY LIPOPROTEINS. THE CHANGES MAY BE VERY MARKED AND COULD HAVE A SERIOUS IMPACT ON THE RISK OF ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE.
Oxandrin®(oxandrolone tablets, USP)CIII
OXANDRIN® oral tablets contain 2.5 mg or 10 mg of the anabolic steroid oxandrolone.
Oxandrin is indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis (See DOSAGE AND ADMINISTRATION).
Published Studies Related to Oxandrin (Oxandrolone)
Long-term oxandrolone treatment increases muscle protein net deposition via improving amino acid utilization in pediatric patients 6 months after burn injury. [2011.05]
BACKGROUND: We recently showed that mechanisms of protein turnover in skeletal muscle are unresponsive to amino acid (AA) infusion in severely burned pediatric patients at 6 months postinjury. In the current study, we evaluated whether oxandrolone treatment affects mechanisms of protein turnover in skeletal muscle and whole-body protein breakdown in pediatric burn patients 6 months postinjury... CONCLUSION: Long-term oxandrolone treatment increased net deposition of leg muscle protein during AA infusion by attenuating protein breakdown, but did not affect whole-body protein breakdown. Copyright (c) 2011 Mosby, Inc. All rights reserved.
Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial. [2011.04.14]
OBJECTIVE: To examine the effect of oxandrolone and the timing of pubertal induction on final height in girls with Turner's syndrome receiving a standard dose of growth hormone... CONCLUSION: Oxandrolone had a positive effect on final height in girls with Turner's syndrome treated with growth hormone, as did late pubertal induction with ethinylestradiol at age 14 years. However, these effects were not additive, so using both had no advantage. Oxandrolone could, therefore, be offered as an alternative to late pubertal induction for increasing final height in Turner's syndrome. Trial registration Current Controlled Trials ISRCTN50343149.
Effect of oxandrolone on glucose metabolism in growth hormone-treated girls with Turner syndrome. [2011.02]
BACKGROUND: The weak androgen oxandrolone (Ox) may increase height but may also affect glucose metabolism in girls with Turner syndrome (TS)... CONCLUSIONS: We conclude that in GH-treated girls with TS, Ox at a dosage of 0.03 or 0.06 mg/kg/day does not significantly affect insulin sensitivity. Insulin sensitivity decreases during GH therapy, to return to a pre-treatment level after discontinuing therapy. Copyright (c) 2010 S. Karger AG, Basel.
Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome. 
BACKGROUND/AIMS: Untreated girls with Turner syndrome (TS) have growth failure, and adult height is, on average, 20 cm less than predicted height. Treatment with growth hormone (GH) is now standard of care. The objective of this study was to investigate the benefit of adding oxandrolone (Ox) to GH in a long-term, randomized, placebo (Pl)-controlled prospective trial to near adult height in TS... CONCLUSIONS: the addition of Ox to GH at mean age 12.0 +/- 1.7 year augmented height gain after 4 years of treatment, slowed breast development and did not affect BMD in girls with TS. Whether initiation of Ox prior to initiation of pubertal development would optimize height gain without impeding breast development will require further study. 2010 S. Karger AG, Basel.
Prospective Study Confirms Oxandrolone-Associated Improvement in Height in Growth Hormone-Treated Adolescent Girls with Turner Syndrome. [2010.08.20]
Background/Aims: Untreated girls with Turner syndrome (TS) have growth failure, and adult height is, on average, 20 cm less than predicted height. Treatment with growth hormone (GH) is now standard of care...
Clinical Trials Related to Oxandrin (Oxandrolone)
Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia [Completed]
The purpose of this study is to evaluate the safety of the drug oxandrolone (a type of
androgen steroid) in patients with Fanconi anemia (FA), and to determine if this drug can
help in the treatment of bone marrow failure in these patients. Androgen steroids are male
hormones that can stimulate the production of red blood cells (the cells which carry oxygen
in the blood) and platelets (cells that help blood clot).
Bioavailability Study of Oxandrolone Tablets Under Fasting Conditions [Completed]
Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer [Completed]
RATIONALE: Oxandrolone and megestrol may help prevent weight loss and improve quality of
life in patients with cancer. It is not yet known whether oxandrolone is more effective than
megestrol in preventing weight loss and improving quality of life in patients who are
receiving chemotherapy for solid tumors.
PURPOSE: This randomized phase III trial is studying oxandrolone to see how well it works
compared to megestrol in preventing weight loss and improving quality of life in patients
who are receiving chemotherapy for solid tumors.
Pilot Study of Goal-Directed Iron Supplementation +/- Oxandrolone for Functional Iron Deficiency of Critical Illness [Not yet recruiting]
The purpose of this trial is to determine if the combination of goal directed iron
supplementation and hepcidin mitigation can safely eliminate both the serum and bone marrow
iron debt of anemic, critically ill trauma patients with functional iron deficiency.
Oxandrolone to Heal Pressure Ulcers [Terminated]
This study is designed to determine whether the use of oxandrolone, an anabolic steroid, can
heal pressure ulcers in persons with spinal cord injury (SCI). In a Feasibility Study,
three VA SCI Units will screen and randomize patients into treatment with oxandrolone or
with placebo. Eleven other sites will screen patients to determine eligibility but will not
treat patients with the agent. Following the Feasibility Study, all sites will participate
in a blinded, randomized treatment study. A total of 400 patients will be enrolled over a
four-year period. Any patient in a participating unit who has chronic SCI and a
difficult-to-heal pelvic ulcer will be eligible for the study if other entry criteria are
met. All enrolled patients will be followed for a period of 24 weeks to determine whether
their target pressure ulcers heal. Those who are healed will be followed for an additional
four weeks to determine whether the ulcer remains healed.
Page last updated: 2011-12-09